ARTICLE | Clinical News
Taiho discontinues Phase III HCC trial
August 1, 2014 12:41 AM UTC
Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) discontinued the 889-patient Phase III ORIENTAL trial evaluating orantinib ( TSU-68) plus transcatheter arterial chemoembolization (TACE) to treat unresect...